Sera Prognostics

Historical price data

Sera Prognostics is a commercial-stage diagnostics company singularly focused on transforming prenatal care through its proprietary proteomic biomarker platform. Its flagship product, the PreTRM® Test, is the first FDA-cleared blood test to provide an individualized risk assessment for spontaneous preterm birth in asymptomatic women. The company's strategy is to drive adoption among providers, payers, and employers by demonstrating improved neonatal outcomes and significant healthcare cost savings, as evidenced by clinical data like the AVERT PRETERM trial. Sera aims to establish itself as a global leader in high-value women's health diagnostics.

Proteomic biomarker discovery platform focused on identifying and validating serum protein signatures, combined with biometric variables, to predict pregnancy complications such as spontaneous preterm birth.

PreTRM holds a first-mover advantage as the only FDA-cleared prognostic blood test for spontaneous preterm birth. Primary competition is from traditional, less sensitive risk assessment methods. The main competitive threat is market inertia rather than a directly comparable diagnostic product.